Search
forLearn
1 / 1 resultsResearch
5 / 31 results
research Thyroid Hormone Receptor Agonist Promotes Hair Growth in Mice
TDM10842, a thyroid hormone receptor activator, was found to effectively promote hair growth in mice.
research Trilayer Dissolving Microneedle for Transdermal Delivery of Minoxidil: A Proof-of-Concept Study
The three-layer microneedle system effectively delivers minoxidil into the skin, showing potential as a safe and efficient treatment for hair loss.
research Application of Validated UV Spectrophotometric and Colorimetric Method to Quantify Minoxidil in the Development of Trilayer Dissolving Microneedle: Proof of Concept in Ex Vivo and In Vivo Studies in Rats
The UV–Vis Spectrophotometry method effectively measures minoxidil in rat skin for alopecia treatment.
research Modern Approaches to the Use of Emulsifiers and Preservatives in Dermatological Medicines
Biogenic surfactants should be explored as safer alternatives in dermatological products.
research Skin Manifestations in COVID-19 and Post-COVID Syndrome
COVID-19 can cause skin issues during and after infection.
Community Join
5 / 35 resultscommunity Why TDM-105795 is not much talked about like GT20029 and HMI 115 despite having far better Trial results?
TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.
community TDM-105795, a new hair loss treatment that actually works!
A new hair loss treatment called TDM-105795 is discussed as a potential replacement or add-on to Minoxidil. Users express hope for new effective treatments.
community TDM-105795 phase 2 results are in!
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.